Essential Tools for Managing Hormone Receptor-Positive Breast Cancer Presented by Learn Look Locate and Walgreens “We know ...

The draft guidance make the regimen available to HR-positive early-stage breast cancer patients with lymph node-positive disease through the Cancer Drugs Fund.

[13] Since this 2004 study, aromatase inhibitor use and any effect on cognition remain under consideration. A 2009 ASCO Breast Cancer Symposium review of five studies evaluated the majority of ...

Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...

A Comprehensive Guide to Aromatase Inhibitors: Essential Tools for Managing Hormone Receptor-Positive Breast Cancer Presented by Learn Look Locate and Walgreens “We know that understanding your ...

A new drug that reduces the risk of breast cancer recurrence has been approved in England. According to an analysis by the ...

DelveInsight's "IBRANCE Market Size, Forecast, and Market Insight Report" highlights the details around IBRANCE, a CDK4/6 inhibitor. The ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

A new twice-daily pill has been approved for NHS use, offering a significant reduction in the risk of certain breast cancers ...

Rapid breast cancer research offers new hope, as discussed by Joyce O’Shaughnessy, MD, regarding HR+/HER2– and HER2+ disease.

to regimens of CDK4/6 inhibitors with aromatase inhibitors like anastrozole or letrozole. According to one of the study's principal investigators – François-Clément Bidard of the Institut ...